Treatment with the TomoTherapy® System Concurrent with Systemic Medication Improves Progression-Free Survival in Patients with Solitary Plasmacytoma of the Bone
Sunnyvale, California (ots/PRNewswire) - Practice-Changing Study Presented at the 2016 Best of ASTRO Meeting Accuray Incorporated (NASDAQ: ARAY) announced today new data showing that 80 percent of patients with solitary plasmacytoma of the bone (SPB) had excellent cancer control four years after receiving ...